Video

Dr. Hamilton on Initial Findings From the LIO-1 Trial in Advanced Metastatic Tumors

Erika P. Hamilton, MD, highlights initial findings from the ​ongoing phase 1b/2 LIO-1 trial in advanced metastatic tumors.

Erika P. Hamilton, MD, director of the Breast Cancer and Gynecologic Cancer Research Program and principal investigator at the Sarah Cannon Research Institute, highlights initial findings from the ​ongoing phase 1b/2 LIO-1 trial (NCT04042116) in advanced metastatic tumors.

​In the phase 1b portion of the study, investigators wanted to determine the recommended dose of lucitanib in combination with nivolumab (Opdivo) in patients with advanced solid tumors.

Encouraging activity​, including complete and partial responses, was demonstrated in 17 patients who received the combination, says Hamilton. ​Additionally, stable disease was reported in 10 patients.

Notably, these data were seen across several tumor types, including those that do not typically respond to immunotherapy​, Hamilton explains. As such, lucitanib/nivolumab is now being further evaluated ​in the phase 2 portion of the trial.

​In the phase 2 setting, patients with gynecologic cancers will start ​on a 6 mg dose of lucitanib once daily. As tolerated, patients will escalate to 8 mg once daily and 10 mg once daily and receive 480 mg of intravenous nivolumab every 28 days, Hamilton concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity